News
Outcome Capital Continues to Expand with the Addition of Charles Simmons
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreNews
NanoHive Medical Announces $7M Series C Financing and Change to Directors Composition
BOSTON, MA, August 5, 2024 – OrthoSpineNews – NanoHive Medical, a leader in 3D-printed titanium spinal interbody fusion devices, announces a $7M Series C Financing to...
Read MoreNews
Maxim Biomedical, Inc. Announces New Minority Investment Partner and Appoints Jonathan Maa as CEO
ROCKVILLE, Md., July 29, 2024 /PRNewswire/ — Maxim Biomedical, Inc., one of the nation’s leading end-to-end rapid diagnostic test developers and manufacturers, has received a new minority...
Read MoreNews
Dx M&A Market Remains Stagnant in H1 2024
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreNews
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
TFF Pharmaceuticals, Inc. announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.
Read MoreNews
Demand for Digital Solutions in Healthcare Remain Strong
Companies need to have a clear, stable business model in terms of who pays for what, he notes, and it helps to establish an ongoing relationship with a payor and/or provider.
Read MoreNews
Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA
Dr. Glezer’s appointment as Managing Director will strengthen Outcome’s healthcare innovation and product launch expertise. BOSTON–Outcome Capital, LLC, a highly specialized life sciences and healthcare...
Read MoreNews
Outcome Capital Expands Its Medical Device and Life Science Services Practices with the Addition of Industry Veteran Peter F. Meyer, Ph.D.
BOSTON–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Peter F. Meyer, Ph.D. has been appointed as...
Read MoreNews
Outcome Capital is happy to announce recent promotions of Thomas Busby, Nick Frame, Mike Casasanta & Carey Gallant
Please join us in congratulating them on their new roles.
Read MoreNews
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read...
Read MoreNews
Outcome Capital Promotes Thomas Busby to Director to Expand Medical Device and Life Science Services Practices
BOSTON — Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted...
Read MoreNews
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma
Outcome Capital is a strategic advisor to Peterson Companies, majority shareholder of Propella Boston – December 28, 2023 — Outcome Capital, a highly specialized life sciences...
Read MoreNews
Outcome Capital Announces Electronic Registry Systems (ERS) Acquisition by Health Catalyst
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a...
Read MoreNews
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into...
Read MoreNews
Outcome Capital and YAFO Capital Announce Strategic Partnership to Expand Global Strategic and Financial Services to Biopharma and Healthcare Clients
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai...
Read MoreNews
Outcome Capital is Top 10 Life Science Financial Provider for 2023 awarded by Life Science Review
Outcome Capital is Top 10 Life Science Financial Provider for 2023 awarded by Life Science Review July 20, 2023 Read the full article here:
Read MoreNews
Outcome Capital and Jumpstart Enter into a Corporate Partnership to Support Early Education in Underserved Communities
Collaboration will support early childhood education programs and address early childhood teacher retention. July 13, 2023 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a...
Read MoreNews
Outcome Capital Named Top 10 M&A Consulting Firms In 2022
Outcome Capital Named Top 10 M&A Consulting Firms December 1, 2022 Outcome Capital leads in Financial Services Review annual listing of 10 companies that are...
Read MoreNews
Outcome Capital Advises ELIOS Vision on Growth Financing Round
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing...
Read MoreNews
Outcome Capital Advises NanoHive Medical on Growth Financing Round
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that NanoHive Medical, LLC closed on an oversubscribed...
Read MoreContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
